Allogene Therapeutics, Inc.
ALLO
$1.45
$0.085.84%
| Weiss Ratings | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.86 | |||
| Price History | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.69% | |||
| 30-Day Total Return | -25.64% | |||
| 60-Day Total Return | -22.46% | |||
| 90-Day Total Return | -41.53% | |||
| Year to Date Total Return | -34.09% | |||
| 1-Year Total Return | -63.66% | |||
| 2-Year Total Return | -68.82% | |||
| 3-Year Total Return | -82.88% | |||
| 5-Year Total Return | -93.81% | |||
| 52-Week High % Change | -67.46% | |||
| 52-Week Low % Change | 11.38% | |||
| Price | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.21 | |||
| 52-Week Low Price | $1.23 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 297.65M | |||
| Enterprise Value | 95.93M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.34 | |||
| Earnings Per Share Growth | -36.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 13,700.00 | |||
| Price/Book (Q) | 0.69 | |||
| Enterprise Value/Revenue (TTM) | 4,360.58 | |||
| Price | $1.45 | |||
| Enterprise Value/EBITDA (TTM) | -0.39 | |||
| Enterprise Value/EBIT | -0.37 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 210.57M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 457 2700 | |||
| Address | 210 East Grand Avenue South San Francisco, CA 94080 | |||
| Website | www.allogene.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,170,372.72% | |||
| Profit Margin | -1,170,863.63% | |||
| Management Effectiveness | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -27.01% | |||
| Return on Equity | -- | |||
| Income Statement | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 22.00K | |||
| Total Revenue (TTM) | 22.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -192.28M | |||
| EBITDA (TTM) | -243.84M | |||
| EBIT (TTM) | -257.48M | |||
| Net Income (TTM) | -257.59M | |||
| Net Income Avl. to Common (TTM) | -257.59M | |||
| Total Revenue Growth (Q YOY) | -100.00% | |||
| Earnings Growth (Q YOY) | 30.12% | |||
| EPS Diluted (TTM) | -1.34 | |||
| EPS Diluted Growth (Q YOY) | 44.15% | |||
| Balance Sheet | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 292.48M | |||
| Cash Per Share (Q) | $1.39 | |||
| Total Current Assets (Q) | 303.39M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 422.18M | |||
| Current Ratio (Q) | 8.541 | |||
| Book Value Per Share (Q) | $1.99 | |||
| Total Assets (Q) | 548.71M | |||
| Total Current Liabilities (Q) | 35.52M | |||
| Total Debt (Q) | 90.76M | |||
| Total Liabilities (Q) | 126.53M | |||
| Total Common Equity (Q) | 422.18M | |||
| Cash Flow | ALLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 75.69M | |||
| Cash from Financing (TTM) | 116.68M | |||
| Net Change in Cash (TTM) | -7.94M | |||
| Levered Free Cash Flow (TTM) | -112.48M | |||
| Cash from Operations (TTM) | -200.30M | |||
